Zobrazeno 1 - 10
of 72
pro vyhledávání: '"E. Friche"'
Publikováno v:
European Journal of Haematology. 42:59-67
Multidrug resistance involves cross-resistance between some of the most important agents in cancer chemotherapy, including the anthracyclines and the vinca alkaloids. It is closely related to an active extrusion of the drugs from the resistant cells,
Publikováno v:
British Journal of Cancer
Eight anthracycline analogs that have been shown to modulate multidrug resistance (Friche et al., Biochem. Pharmacol., 39, 1721-1726; 1990) were tested for their inhibitory effect on the photolabelling of P-glycoprotein. We photoaffinity labelled P-g
Autor:
Bridget T. Hill, L. K. Hosking, S. McClean, S. A. Shellard, W. C. M. Dempke, R. D. H. Whelan, M. Sehested, E. Friche, E. J. F. Demant, P. B. Jensen, B. P. Kopnin, B. Wolf, A. Seidel, M. Nickelsen, I. Brandt, G. Heinemann, M. Dietel, S. Bremer, T. Hoof, B. Tümmler, H. J. Broxterman, C. H. M. Versantvoort, C. M. Kuiper, N. Feller, G. J. Schuurhuis, J. Lankelma, S. Gupta, T. Tsuruo, C. Kim, S. Gollapudi, A. Bittl, M. Nap, W. Jäger, B. Lathan, N. Lang, N. T. Raikhlin, A. G. Perevozchikov, J. L. Volodina, T. Licht, H. H. Fiebig, K. J. Bross, F. Herrmann, R. Mertelsmann, I. Bashir, K. Sikora, C. S. Foster, M. Castagna, P. Viacava, M. Cianfrigliao, A. Favati, P. Collecchi, M. A. Caligo, G. Cipollini, G. Bevilacqua, D. Schrenk, T. W. Gant, J. A. Silverman, S. S. Thorgeirsson, A. Harstrick, Z. G. Zhang, H. J. Schmoll, Y. Rustum, M. Mitze, T. Beck, W. Weikel, C. Brumm, P. G. Knapstein, T. McDonald, P. Gardner, N. Kang, S. A. M. van der Heyden, H. J. Elst, U. Stein, B. Jandrig, H. Krause, P. Schmidt-Peter, J. Frege, V. Wunderlich, E. Boven, C. K. van Kalken, H. M. Pinedo, W. Gebauer, E. Fallgren-Gebauer, M. Diete, T. Wagner, M. R. Müller, K. Lennartz, H. R. Nowrousian, S. Seeber, A. A. Shtil, A. R. Kazarov, A. V. Gudkov, A. A. Stavrovskaya, F. H. Djuraeva, T. P. Stromskaya, A. Noller, G. Frese, M. Neumann, A. Wilisch, H. Probst, V. Gekeler, R. Handgretinger, H. Schmidt, C. P. Muller, R. Dopfer, T. Klingebiel, D. Niethammer, S. Weger, H. Diddens, E. Daumiller, A. Bunge, R. Lilischkis, A. Salmassi, M. Kopun, H. Scherthan, C. Granzow, I. Leuschner, D. Schmidt, H. Hoffmann, D. Harms, G. V. Scagliotli, E. Leonardo, S. Cappia, G. Esposito, M. Tombesi, M. Cianfriglia, G. V. Esposito, N. Merendino, M. Viora, M. Caserta, E. Tritarelli, E. Rocca, G. Boccoli, P. Samoggia, C. Fossati, U. Testa, C. Peschle, J. L. Darling, S. M. Ashmore, D. C. Peterson, D. G. T. Thomas, R. A. Kramer, R. Stanlunas, T. Summerhayes, T. Lion, R. H. Shoemaker, L. Wu, A. Smythe, M. R. Boyd, W. T. Beck, M. K. Danks, J. S. Wolverton, M. Chen, B. Y. Bugg, D. P. Suttle, C. V. Catapano, D. J. Fernandes, F. Gieseler, F. Boege, R. Erttmann, H. Arps, L. Zwelling, K. Wilms, H. Biersack, G. J. L. Kaspers, R. Pieters, E. Klumper, F. C. de Waal, E. R. van Wering, A. J. P. Veerman, C. A. Schmidt, F. Lorenz, A. Schäfer, A. Kirsch, W. Siegert, D. Huhn, W. E. Simon, G. Siebert, M. Schneider, M. Oettling, A. Reymann, R. Entmann, S. Schmidt, C. Woermann, C. Windmeier, I. Herzig, B. Schaefer, H. J. Heidebrecht, H. H. Wacker, H. Künnemann, Th. H. M. van Heijningen, M. L. Slovak, J. P. A. Baak, K. Steidtmann, A. -M. J. Fichtinger-Schepman, B. I. Hill, K. J. Scanlon, W. J. Zeller, G. Chen, J. A. Gietema, E. G. E de Vries, D.Th Sleijfer, P. H. B. Willemse, H. J. Guchelaar, D. R. A. Uges, P. Aulenbacher, R. Voegeli, N. H. Mulder, C. Skrezek, H. Bertermann, H. Eichholtz-Wirth, R. Born, H. Bier, M. Koch, G. Bernhardt, K. Hählen, H. Reile, C. H. van Zantwijk, T. Görögh, B. Lippert, J. A. Werner, J. E. Eickbohm, G. H. Mickiseh, M. M. Gottesman, I. Pastan, J. Hofmann, A. Wolf, M. Spitaler, G. Bock, H. Grunicke, H. Ponstingl, I. Roth, C. Dörner, G. Looft, G. J. Ossenkoppele, G. L. Scheffer, G. Atassi, A. Pierre, L. Kraus, S. Leonce, G. Regnier, A. Dhainaut, M. Stöhr, C. Rohlff, R. I. Glazer, Y. S. Cho-Chung, V. Höllt, M. Kouba, G. Vogt, H. Allmeier, N. I. Nissen, S. Cros, N. Guilbaud, T. Dunn, M. Berlion, J. P. Bizzari, A. M. Messing, A. Matuschek, I. Mutter, J. C. W. Kiwit, L. Bastian, P. E. Goretzki, A. Frilling, D. Simon, H. D. Röher, A. Reichle, F. Altmayr, J. Rastetter, C. Erbil, G. Jaques, M. Maasberg, K. Havemann, K. Häußermann, H. -J. Heidebrecht, W. Van de Vrie, E. E. O. Gheuens, N. M. C. Durante, E. A. De Bruijn, R. L. Marquet, A. T. Van Oosterom, A. M. M. Eggermont, M. W. Stow, S. E. Vickers, J. R. Warr, E. Roller, M. Eichelbaum, B. Klumpp, J. Krause, K. Schumacher, S. Hörner, A. Laßmann, U. Traugott, E. Schlick, D. Bürkle, BW Futscher, AF List, WS Dalton, E. Ladda, K. Bühl, A. Weimer, C. Eser, K. Hamprecht, K. P. Schalk, C. Jackisch, B. Brandt, M. Blum, F. Louwen, K. Schulz, J. P. Hanker, U. Rüther, A. Schmidt, H. A. G. Müller, C. Nunnensiek, H. Bader, F. Eisenberger, P. Jipp, B. Niethammer, C. Muller, V. Ling, F. Joncourt, S. Redmond, K. Buser, M. Fey, A. Tobler, K. Brunner, A. Gratwohl, T. Cerrry, V. Nuessler, R. Pelka-Fleischer, C. Nerl, B. Beckert, W. Wilmanns, S. Hegewisch-Becker, M. Fliegner, A. Zander, D. K. Hossfeld, J. Blanz, K. Mewes, G. Ehninger, K. -P. Zeller, H. Schuldes, G. Herrmann, W. Boeckmann, R. Schroeder, D. Jonas, K. -H. Zurborn, H. D. Bruhn, L. Uharek, B. Glass, W. Gassmann, H. Loeffler, W. Mueller-Ruohholtz, W. Mueller-Ruchholtz, K. Jaquet, H. Kreipe, J. Felgner, H. J. Radzun, M. R. Parwaresch, EA Kogan, NN Mazurenko, SM Sekamova, H. Wolf, K. Röhe, K. Wilkens, M. Clausen, E. Henze, J. van der Bosch, S. Rüller, M. Schlaak, U. Köhl, D. Schwabe, E. Rohrbach, E. Montag, S. Bauer, J. Cinatl, I. Cinatl, M. Mainke, H. Geiss, B. Kornhuber, H. Juhl, H. Stritzel, H. Kalhoff, W. Schniegel, T. Menke, B. Pröbsting, P. Schulze-Westhoff, J. Boos, J. Weidner, N. Wedemeyer, K. Wiedorn, Y. Ueda, S. Blasius, P. Wuisman, W. Böcker, A. Roessner, B. Dockhorn-Dworniczak, D. Ramm, J. Knebel, W. Sass, M. Aufderheide, J. Seifert
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 117:S89-S120
Publikováno v:
British Journal of Cancer
Verapamil has been proposed to modulate the multidrug resistance phenotype by competitive inhibition of an energy dependent efflux of cytotoxic drug. However, the accumulation of both 14C-verapamil and 3H-verapamil was similar in wild type EHR2 and m
Publikováno v:
Biochemical pharmacology. 45(10)
In contrast to the classic anthracyclines (doxorubicin and daunorubicin), aclarubicin (ACLA) does not stimulate topoisomerase II (topo II) mediated DNA-cleavage. This distinction may be important with respect to topo II-related drug resistance, and t
Autor:
M K, Danks, M R, Warmoth, E, Friche, B, Granzen, B Y, Bugg, W G, Harker, L A, Zwelling, B W, Futscher, D P, Suttle, W T, Beck
Publikováno v:
Cancer research. 53(6)
Five cell lines selected for resistance to the cytotoxicity of inhibitors of DNA topoisomerase II have point mutations in the gene that codes for the M(r) 170,000 form of this enzyme. In each case, the mutation results in an amino acid change in or n
31P and 13C NMR spectroscopic study of wild type and multidrug resistant Ehrlich ascites tumor cells
Publikováno v:
Oncology research. 5(3)
Steady-state 31P NMR spectra of wild type EHR2 Ehrlich ascites tumor cells and multidrug resistant EHR2/DNR+ cells, immobilized in agarose threads, and continuously perfused with medium, showed temperature-dependent differences in the levels of intra
Publikováno v:
Cancer research. 52(20)
Reduced drug accumulation is the most common functional change accompanying development of P-glycoprotein-associated multidrug resistance. One of our laboratories showed earlier that the anthracycline analogue 4'-deoxy-4'-iododoxorubicin (DIDOX) was
Publikováno v:
Cancer research. 52(10)
The classical multidrug resistance (MDR) phenotype is characterized by cross-resistance between a number of chemically unrelated drugs due to an increased efflux across the plasma membrane via a P-glycoprotein-mediated mechanism. The epipodophyllotox
Autor:
P B, Jensen, P S, Jensen, E J, Demant, E, Friche, B S, Sørensen, M, Sehested, K, Wassermann, L, Vindeløv, O, Westergaard, H H, Hansen
Publikováno v:
Cancer research. 51(19)
The effect of combinations of the anthracyclines aclarubicin and daunorubicin was investigated in a clonogenic assay using the human small cell lung cancer cell line OC-NYH and a multidrug-resistant (MDR) murine subline of Ehrlich ascites tumor (EHR2